Search results
Results from the WOW.Com Content Network
Targeted expression of oncogenes in mouse mammary epithelial cells is a way of modeling human breast cancer. Mutation or over expression of oncogenes can be kept under controlled expression in a very specific cellular context rather than throughout the organism.
[13] [14] BRCA1 and BRCA2 have been described as "breast cancer susceptibility genes" and "breast cancer susceptibility proteins". The predominant allele has a normal tumor suppressive function whereas high penetrance mutations in these genes cause a loss of tumor suppressive function, which correlates with an increased risk of breast cancer. [15]
6862 20997 Ensembl ENSG00000164458 ENSMUSG00000062327 UniProt O15178 P20293 RefSeq (mRNA) NM_001270484 NM_003181 NM_001366285 NM_001366286 NM_009309 RefSeq (protein) NP_001257413 NP_003172 NP_001353214 NP_001353215 NP_033335 Location (UCSC) Chr 6: 166.16 – 166.17 Mb Chr 17: 8.65 – 8.66 Mb PubMed search Wikidata View/Edit Human View/Edit Mouse T-box transcription factor T, also known as ...
[13] [11] BRCA1 and BRCA2 have been described as "breast cancer susceptibility genes" and "breast cancer susceptibility proteins". The predominant allele has a normal, tumor-suppressive function whereas high penetrance mutations in these genes cause a loss of tumor-suppressive function which correlates with an increased risk of breast cancer. [14]
Ch8 Approximately 1% to 2% of men with a BRCA1 mutation will develop breast cancer by age 70. Approximately 6% of men with a BRCA2 mutation will develop breast cancer by age 70, which is approximately equal to the risk for women without a BRCA mutation. Very few men, with or without a predisposing mutation, develop breast cancer before age 50 ...
Studies show that a CHEK2 1100delC corresponds to a two-fold increased risk of breast cancer and a 10-fold increased risk of breast cancer in males. [10] A CHEK2 mutation known as the I157T variant to the FHA domain in exon 3 has also been linked to breast cancer but at a lower risk than the CHEK2*1100delC mutation. The estimated fraction of ...
Mutations of this gene are a step in the development of many cancers, specifically glioblastoma, lung cancer, breast cancer, and prostate cancer. Genes corresponding to PTEN [7] have been identified in most mammals for which complete genome data are available.
The laboratory mouse has been instrumental in investigating the genetics of human disease, including cancer, for over 110 years. [1] The laboratory mouse has physiology and genetic characteristics very similar to humans providing powerful models for investigation of the genetic characteristics of disease.